文章：

在选择性内放射治疗的患者中，体外细胞免疫功能可预测生存率

In Patients Treated by Selective Internal Radiotherapy, Cellular In Vitro Immune Function Is Predictive of Survival

原文发布日期：11 August 2023

DOI: 10.3390/cancers15164055

类型: Article

开放获取: 是

英文摘要：

In patients with liver malignancies, the cellular immune function was impaired in vitro after selective internal radiotherapy (SIRT). Because immunosuppression varied substantially, in the current study, we investigated in 25 SIRT patients followed up for ten years whether the lymphocyte function was correlated with survival. Peripheral blood mononuclear cells were stimulated with four microbial antigens (tuberculin, tetanus toxoid,Candida albicansand CMV) before therapy and at four time points thereafter, and lymphocyte proliferation was determined by H3-thymidine uptake. The median sum of the responses to these four antigens decreased from 39,464 counts per minute (CPM) increment (range 1080–204,512) before therapy to a minimum of 700 CPM increment on day 7 after therapy (0–93,187,p< 0.0001). At all five time points, the median survival in patients with weaker responses was 2- to 3.5-fold shorter (p< 0.05). On day 7, the median survival in patients with responses below and above the cutoff of a 2 CPM increment was 185 and 523 days, respectively (χ2= 9.4,p= 0.002). In conclusion, lymphocyte function could be a new predictor of treatment outcome after SIRT.

摘要翻译： 

在肝脏恶性肿瘤患者中，选择性内放射治疗后体外细胞免疫功能出现损伤。由于免疫抑制程度存在显著差异，本研究对25例接受选择性内放射治疗并随访十年的患者进行了研究，旨在探讨淋巴细胞功能是否与生存期相关。在治疗前及治疗后四个时间点，采用四种微生物抗原（结核菌素、破伤风类毒素、白色念珠菌和巨细胞病毒）刺激外周血单核细胞，并通过H3-胸腺嘧啶核苷摄入法测定淋巴细胞增殖情况。对这四种抗原反应的中位总和值从治疗前的每分钟39,464计数增值（范围1080-204,512）降至治疗后第7天的最低值每分钟700计数增值（范围0-93,187，p<0.0001）。在所有五个检测时间点，反应较弱患者的中位生存期缩短了2至3.5倍（p<0.05）。治疗后第7天，反应值低于和高于2计数增值临界点的患者中位生存期分别为185天和523天（χ2=9.4，p=0.002）。综上，淋巴细胞功能可能成为选择性内放射治疗后疗效预测的新指标。

原文链接：

In Patients Treated by Selective Internal Radiotherapy, Cellular In Vitro Immune Function Is Predictive of Survival